| 晶泰控股 |
沈南鹏 |
减持 |
-67814779 |
20295.84万股 |
0.05% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
UBS Group AG |
增持 |
21660067 |
2166.01万股 |
0.10% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Invesco Developing Markets Fund |
增持 |
25099800 |
2509.98万股 |
0.11% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Invesco Advisers, Inc. |
增持 |
26390400 |
2639.04万股 |
0.12% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
JPMorgan Chase Bank, National Association |
增持 |
11915110 |
1191.51万股 |
0.05% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
童小幪 |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
童小幪 |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
XYXY Holdings Ltd. |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Group, LLC |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Group Holdings Ltd. |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Investment Management Limited |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Opportunities Master Fund |
增持 |
12934741 |
1293.47万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
XYXY Holdings Ltd. |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Group, LLC |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Group Holdings Ltd. |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Investment Management Limited |
增持 |
14074800 |
1407.48万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
Boyu Capital Opportunities Master Fund |
增持 |
12934741 |
1293.47万股 |
0.06% |
好仓 |
2025-05-23 |
| MIRXES-B |
北京浔瑞企业管理合伙企业(有限合伙) |
增持 |
16649200 |
1664.92万股 |
0.06% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
HHLR CF, L.P. |
增持 |
11435800 |
1143.58万股 |
0.05% |
好仓 |
2025-05-23 |
| 恒瑞医药 |
HHLR Advisors, Ltd. |
增持 |
11435800 |
1143.58万股 |
0.05% |
好仓 |
2025-05-23 |
